華潤醫藥(03320.HK)旗下治療高血壓等藥物獲藥品註冊證書
華潤醫藥(03320.HK)公布,旗下華潤賽科的氨氯地平阿托伐他汀鈣片、枸櫞酸西地那非片於10月26日獲國家藥監局簽發《藥品註冊證書》,並視同通過一致性評價。
氨氯地平阿托伐他汀鈣片適用於需氨氯地平和阿托伐他汀聯合治療的患者。其中,氨氯地平用於高血壓的治療,用於慢性穩定性心絞痛、血管痙攣性心絞痛及經血管造影證實的冠心病的治療;阿托伐他汀用於高膽固醇血症及冠心病的治療。
華潤醫藥指,根據全球71國家藥品銷售數據庫顯示,2020年氨氯地平阿托伐他汀鈣片全球銷售額為1.93億美元。國內市場方面,根據國家藥監局網站信息顯示,中國境內已批准上市的氨氯地平阿托伐他汀鈣片生產企業共3家。根據米內網數據顯示,2020年氨氯地平阿托伐他汀鈣片銷售總額為7.96億元人民幣。
枸櫞酸西地那非片適用於治療勃起功能障礙。華潤醫藥指,根據全球71國家藥品銷售數據庫顯示,2020年枸櫞酸西地那非片全球銷售額為16.24億美元。國內市場方面,根據國家藥監局網站信息顯示,中國大陸境內已批准上市的枸櫞酸西地那非片生產企業11家。根據米內網數據顯示,2020年枸櫞酸西地那非片銷售總額為8,724萬元人民幣。
華潤醫藥指,此次獲得《藥品註冊證書》,將有助於進一步豐富華潤雙鶴產品線,提升公司產品的市場競爭力,同時對集團整體經營業績的提升起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.